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Dynamic changes of cytotoxic T lymphocytes
(CTLs), natural killer (NK) cells, and natural killer T
(NKT) cells in patients with acute hepatitis B
infection
Jun Li1,2*†, Yaping Han1†, Ke Jin1, Yufeng Wan1, Shixia Wang2,3, Bo Liu1, Yuan Liu1, Shan Lu2,3 and Zuhu Huang1,2*
Abstract
Background: The goal of this study is to observe changes in HBcAg-specific cytotoxic T lymphocytes (CTLs),
natural killer (NK) and natural killer T (NKT) cells from peripheral blood and to relate such changes on viral
clearance and liver injury in patients with acute hepatitis B (AHB).
Methods: Dynamic profiles on the frequency of HLA-A0201-restricted HBcAg18-27 pentamer complex (MHC-
Pentamer)-specific CTLs and lymphocyte subsets in AHB patients were analyzed in addition to liver function tests,
HBV serological markers, and HBV DNA levels. ELISPOT was used to detect interferon-gamma (INF-g) secretion in
specific CTLs stimulated with known T cell epitope peptides associated with HBV surface protein, polymerase, and
core protein.
Results: HBV-specific CTL frequencies in AHB patients were much higher than in patients with chronic hepatitis B
(CHB) (p < 0.05). HBeAg and HBV DNA disappeared earlier in AHB patients with a high frequency of HBV-specific
CTLs compared with those with a low frequency of HBV-specific CTLs (p = 0.001 and 0.024, respectively). INF-g
spots of effector cells stimulated by Pol575-583, Env348-357, or Core18-27 epitope peptides were significantly
greater in AHB patients than in CHB patients (p < 0.01). CD3+CD8+ T cell numbers in AHB patients was more than
observed in the healthy control group from the first to the fourth week after admission (p = 0.008 and 0.01,
respectively); the number of CD3+CD8+ T cells and frequency of HBcAg18-27-specific CTLs in AHB patients reached
peak levels at the second week after admission. NK and NKT cell numbers were negatively correlated with the
frequency of HBcAg-specific CTLs (r = -0.266, p = 0.05).
Conclusions: Patients with AHB possess a higher frequency of HBcAg-specific CTLs than CHB patients. The
frequency of specific CTLs in AHB patients is correlated with HBeAg clearance indicating that HBV-specific CTLs
play an important role in viral clearance and the self-limited process of the disease. Furthermore, NK and NKT cells
are likely involved in the early, non-specific immune response to clear the virus.
Background
The clinical manifestations and outcomes of hepatitis B
virus (HBV) infection depend mainly on the intensity
and type of anti-viral immunity produced by the
infected individual. In patients with acute HBV infec-
tion, the specific immune response induced against
HBV is a strong, polyclonal, multi-specific cellular
immune response, and the virus is eventually cleared.
However, in patients with chronic hepatitis B, the speci-
fic cellular immune response to HBV is weak and the
body is immune-tolerant to HBV. Previous studies have
shown that the roles of immune cells in the anti-viral
immune response are not independent [1] and instead,
cooperation among different subsets of immune cells
may exist. In the current study, we analyzed the fre-
quency and functional changes of specific cytotoxic T
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lymphocytes (CTLs) in AHB patients and the possible
dynamic relationship between lymphocyte subsets and
the number of NK and NKT cells. We also explored the
roles of specific and non-specific immune cells in viral
clearance and cell injury. The results from these studies
could provide us with the means to evaluate the clinical
prognosis of patients with hepatitis B and to develop
prevention and control strategies.
In the current report, we show that patients with AHB
possess a higher frequency of HBcAg-specific CTLs than
CHB patients and the frequency of specific CTLs in
AHB patients is correlated with HBeAg clearance indi-
cating that HBV-specific CTLs play an important role in
viral clearance and the self-limited process of the
disease.
Methods
Subjects
This study included 131 inpatients and outpatients with
HBV infection from the Infectious Diseases Department
of Jiangsu Province Hospital from August 2006 to July
2010. The clinical features of these patients are shown
in Table 1. The subjects were classified according to
HLA genotype. HLA-A0201-positive patients made up
the HBV-specific CTLs test group and HLA-A0201-
negative patients made up the specific antigen epitope
control group. The diagnosis of AHB was based on typi-
cal clinical manifestations, i.e., increased alanine transa-
minase (ALT) to at least 2.5 times the normal upper
limit, no history of hepatitis B, a positive test for hepati-
tis B surface antigen (HBsAg) and serum anti-HBc IgM
[2], ALT returning to normal and the disappearance of
HBsAg, and HBeAg within six months after the onset of
illness. The diagnosis of CHB was based on the guide-
lines for chronic hepatitis B diagnosis of the American
Association for the Study of Liver Diseases (AASLD)
[3]. Patients who had an infection with other hepatitis
viruses, a history of autoimmune disease, a history of
hepatotoxic drug use or a history of nucleoside anti-
HBV drug or interferon use were excluded. A total of
36 healthy volunteers with normal liver function, nega-
tive HBV serological markers, and no history of hepatitis
A virus (HAV), hepatitis C virus (HCV), hepatitis D
virus (HDV), hepatitis E virus (HEV), cytomegalovirus,
or Epstein Barr virus (EBV) infection were used as a
negative control group for the detection of specific
CTLs. The current study was reviewed and approved by
the Institutional Ethics Committee and consents were
received from patients included in the current study.
Major reagents
A genomic DNA mini-spin kit was purchased from
QIAGEN (Cat. No. 12143). Reverse sequence-specific
oligonucleotide probes (R-SSO) and genotyping reagents
were provided by One Lambda Inc. (R-SSO-008N, CA,
USA). Sequence-specific primers (polymerase chain
reaction-sequence specific primer, PCR-SSP) and HLA
high-resolution typing kits were purchased from Invitro-
gen (U.S. Batch: 27463). The PCR thermocycler (PCT-
200TM) was purchased from M.J Company (USA). The
gel imaging analysis system was purchased from Spring
(Transilluminator 202D, Cold Spring Harbor, USA). The
HBV DNA quantitative detection kit was purchased
from PiJi (Shenzhen), and the HBV DNA frequency
detector was a LightCycler 1.0 purchased from Roche
(USA). The HBcAg18-27 MHC/Pentamer-PE was con-
structed by Proimmune (U.K.). The HLA-A0201-
limitted epitope peptides Corel8-27 (FLPSDFFPSV),
Pol575-583 (FLLSLGIHL), Env348-357 (GLSPTVWISV),
and HCV Core132-140 (DLMGYIPLV) were synthesized
by GL Biochem Ltd (Shanghai). ELISPOT kit was pur-
chased from U-Cytech (Netherlands). The mouse-anti-
human CD3-PerCP-Cy5.5 and four-color lymphocyte
subset detection kits were purchased from BD Bios-
ciences (USA). The mouse anti-human CD8-APC was
purchased from Beckman Coulter Corp. (USA). HBV
serological markers detection kit and instrument
(Axsym 1.0) were from Abbott (USA). Automatic Bio-
chemical Detector (AU5400) and associated test kits
were from Olympus (Japan).
Analysis of the HLA-A2 allele using high-resolution
PCR-SSP
Analysis of the HLA-A2 allele was performed as
described elsewhere [4]. Briefly, genomic DNA was
extracted from 200 μl of sodium citrate-anticoagulated
venous blood. DNA, at a concentration of >50 ng/μl
and OD260/280 between 1.7-2.0, was used as the tem-
plate for HLA-A2 allele analysis. Total reaction volume
was 23 μl, including 2 μl of 2.5 pmol/μl forward primer,
Table 1 General information about the study subjects
Variant Case (131) Normal
(50)
AHB (53) CHB (78)
Sex Male 38 51 33
Female 15 27 17
Age 18-64
(40.2)
20-53
(31.5)
20-52 (27.5)
HLA-A0201 Positive 18 21 10
Gene frequency
(%)
33.96 26.9 20.0
Transmission route Sexual 4 0
NA
Vertical 0 21 NA
Injection 2 0 NA
Nonspecific reason 47 57 NA
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2 μl of 2.5 pmol/μl reverse primer, 0.5 μl of 5 U/μl Hot-
start Taq enzyme, 2 μl of 10*Buffer, 0.5 μl of 10 mMol
dNTPs, 6 μl of ddH2O; the reaction conditions of PCR
were 96°C, 1 min, 1 cycle; 96°C for 25 s, 70°C for 50 s,
72°C for 45 s, 5 cycles; 96°C for 25 s, 65°C for 50 s, 72°
C for 45 s, 21 cycles; 96°C for 25 s, 55°C for 60 s, 72°C
for 120 s, 4 cycles. Electrophoresis of the amplified pro-
ducts was done in a 2% agarose gel stained with ethi-
dium bromide (EB); bands were observed under the UV
lamp with a wavelength of 254 nm and UniMatc soft-
ware was used to compare with the standard map to
determine the genotype. A gel imaging analysis system
was used for detection and analysis. High-resolution
results were obtained with Unityper analysis software.
Patients with HLA-A0201 genotype were included into
the HBV-specific group.
Detection of HBcAg-specific CTLs
Detection of HBcAg-specific CTLs was done as pre-
viously reported [4]. Briefly, 10 μl HLA-A0201 restricted
epitope HBcAg18-27 MHC/Pentamer-PE (amino acid
sequence was FLPSDFFPSV) and 100 μl 1 × 10E6 cells/
ml peripheral blood lymphocytes were added into tubes
special for flow cytometry. The tubes were placed into
4°C in the dark for 20 min, and centrifuged at 500 g for
5 min. The supernatant was discarded, the cells were
washed using 3 ml pH7.2 PBS containing 0.1% BSA, the
cells were resuspended at 1000 r/min for 30 s, and 20 μl
anti-CD3 monoclonal antibody labeled with PerCP
Cy5.5 and 20 μl anti-CD8 monoclonal antibody labeled
with APC were added. The tubes were placed in the
dark at 4°C for 20 min, and were washed then fixed
using 500 μl 1% paraformaldehyde. FACS was used for
quantitative analysis of the percentage of HBcAg18-27
MHC-Pentamer-PE/CD8-APC double-positive cells with
CD3 gating.
Detection of epitope peptide specific CTLs
Detection of epitope peptide-specific CTLs was per-
formed as described elsewhere [5]. The 96-well polyvi-
nylidene plates were pre-coated with 2 μg/ml of mouse-
anti-human interferon gamma (IFN-g) mAb and incu-
bated at 4°C overnight, washed six times with sterile
PBS containing 1% FCS. 100 μl PBMC suspension was
added into the wells to ensure 2 × 10E5 cells per well.
100 μl serum-free medium was added to blank control
wells; 10 μl PHA at a final concentration of 4 mg/L was
added to the positive control wells, which contained 2 ×
10E4 cells per well; HLA-A0201-restricted epitope at a
final concentration of 10 μg/ml was added to the detec-
tion wells; HLA-A0201-restricted HCV Core132-140
(DLMGYIPLV) at a final concentration of 10 μg/ml was
added to the negative control wells. Plates were incu-
bated in 5% CO2 at 37°C for 24 h. The medium and
cells were removed and 200 μl deionized water was
added and incubated on ice for 10 min. After washing
ten times with PBS containing 0.05% Tween-20, 100 μl
biotinylated anti-IFN-g antibody was added to each well
and plates were incubated at 37°C for 1 hour. The plates
were washed again and incubated with HRP-labeled
streptavidin at 37°C for 1 h. After washing the plates
again, 100 μl of AEC solution was added to each well
and incubated at room temperature for 30 min. The
color reaction was stopped by washing plates with deio-
nized water. An ELISPOT automatic analysis system
was used to count the spots; each spot represented an
IFN-g-secreting cell and the average of the three wells
was taken as the detecting value. The number of epitope
peptide-specific CTLs was determined as the spots per
each epitope peptide group minus the spots in the nega-
tive control group.
Detection of peripheral blood lymphocyte subsets
The cells were marked as previously reported [6] and
gated for leukocyte common antigen (CD45)-positive
cells. Lymphocyte surface markers were then analyzed
by two parameters according to a forward and side scat-
ter two-parameter point diagram. The results were ana-
lyzed using CellQuest (BD, USA) software.
HBsAg, HBeAg and HBV-DNA detection
HBV HBsAg and HBeAg levels were determined using
the Architect system (Abbott, HBsAg and HBeAg chemi-
luminescent microparticle immunoassay kit). The levels
of HBV DNA were detected using a LightCycler 1.0.
Blood biochemistry
ALT, AST, and total bilirubin (TBIL) levels were
detected using automatic Biochemical Detector
(AU5400) and associated test kits from Olympus, Japan.
Statistical analysis
The experimental data were analyzed using SPSS 13.0
software. Quantitative data were described using “mean
± standard deviation”. Comparisons between groups
were analyzed using variance or nonparametric tests
(Kruskal-Wallis and Mann-Whitney U tests). The rela-
tionship between the two quantitative indicators was
analyzed using Pearson correlation analysis. p < 0.05
was considered significant.
Results
HLA allele test
High-resolution SSP-PCR results showed that 18 out of
53 AHB patients were HLA-A0201 positive (gene fre-
quency was 33.96%), 21 out of 78 CHB patients were
HLA-A0201 positive (gene frequency was 26.9%), and
10 out of 50 healthy controls were HLA-A0201 positive
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(gene frequency was 20.0%). Although the frequencies of
HLA-A0201 positive cases in AHB and CHB were
higher than those in healthy controls, this difference
was not significant.
Differences in specific CTLs in different HBV infected
patient groups
Thirty-nine HLA-A0201-positive patients were included
in the HBcAg-specific CTLs test group. Among these
patients, there were 18 AHB patients and the frequen-
cies of HBcAg-specific CTLs were 1.64 (0.22~2.97), 0.97
(0.35~4.59), 1.05 (0.47~2.34), 0.43 (0.31~1.05), 0.38
(0.24~0.61), and 0.25 (0.16~0.33) from the first to the
sixth week after admission, respectively. CTLs frequen-
cies during the first, second, and third week were signifi-
cantly higher than those from 21 CHB patients, Z =
-4.226, -3.804, and -2.537, respectively, (p < 0.05)
(Figure 1). In addition, the frequency of HBcAg-specific
CTLs in 10 healthy controls was 0.00 (0.00~0.03), which
was significantly lower than observed in AHB and CHB
patients (p < 0.01).
Dynamic changes in liver injury and HBV serological
markers in AHB patients
The first evaluation of liver function was carried out
when AHB patients were admitted; serum HBV DNA,
HBV markers, ALT, AST, and TBIL were then detected
every week for a total of six measurements, except for
HBV DNA quantification and HBV serological marker
detection, which continued until they turned negative.
HBsAg and HBV DNA were undetectable within three
months in all AHB patients. Our results showed ALT,
AST, and TBIL in AHB patients were at peak levels
upon admission, and had returned to normal in most
patients by six weeks. Among the 53 AHB patients,
there were 14 patients (26.4%) with undetectable serum
HBV DNA upon admission, nine patients turned nega-
tive at the second week after admission, 12 at the third
week, six at the fourth week, six at the fifth week after
admission, and the remaining patients turned negative
at the sixth week. Also, among the 53 AHB patients,
there were 27 patients (50.9%) with negative serum
HBeAg upon admission, five patients turned negative at
the second week after admission, eight at the third
week, four patients at the fourth week, one patients at
the fifth week, and eight at the sixth week. Among these
same patients, there were nine patients (17.0%) with
negative serum HBsAg upon admission, nine patients
turned negative at the second week after admission, 14
patients at the third week, two patients at the fourth
week, four patients at the fifth week, seven patients at
the sixth week, and the remaining patients turned nega-
tive during the period from seventh to eleventh week.
The relationship between dynamic changes in HBcAg-
specific CTLs frequency, liver injury, and viral clearance
HBcAg-specific CTLs levels among the 18 HLA-A0201-
positive AHB patients were tested every week following
admission for a total of six measurements (the test upon
admission was designated as the first week). Peak
HBcAg-specific CTLs in AHB patients occurred at the
second week after admission, started to decline at the
third week, and declined to the lowest level at the fifth
week. With an increase in the frequency of HBcAg-spe-
cific CTL, serum HBV DNA declined rapidly, the level
of serum HBsAg and HBeAg showed the same ten-
dency, and ALT and other live function indictors also
returned to normal (Figure 2 and Figure 3). After the
HBV DNA and HBeAg turned negative, HBV-specific
CTL stayed at a low level. Among the 18 AHB patients,
11 patients had HBcAg-specific CTLs frequencies
greater than 1.0, while seven patients had frequencies <
1.0. The disappearance of HBeAg and HBV-DNA in the
patients whose CTLs frequency were greater than 1.0
occurred earlier than that in the patients whose CTLs
frequency were less than 1.0, t = -4.313 and -2.485,
respectively (p = 0.001 and 0.024).
Function Comparison between the CTLs of AHB patients
who were in acute phase and the CTLs of CHB patients
Pol575-583, Env348-357, or Core18-27 epitope peptides
were used to stimulate peripheral blood mononuclear cells
(PBMCs) from HBV-infected patients and ELISPOT was
used to detect the INF-g secreting cells in order to under-
stand the INF-g and other cytokine-secreting ability of the
Figure 1 Frequency of HBcAg 18-27 epitope-specific CTLs. AHB
indicated that the first HBcAg18-27 Pentamer test result after
admission among the HLA-A0201-positive patients with acute
hepatitis B; CHB indicated that the HBcAg18-27 Pentamer test result
among the HLA-A0201-positive patients with chronic hepatitis B;
Normal indicated that the HBcAg18-27 Pentamer test result among
the HLA-A0201-positive subjects in the healthy control group. The
differences among these groups were significant, p = 0.0 01.
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specific CTLs. Our results indicated that the spot-forming
units (SFU) of AHB patients at the first week after admis-
sion was 132.8 ± 10.8, 194.8 ± 17.7, and 240.4 ± 31.8 for
Pol575-583, Env348-357 or Core18-27 epitope peptides,
respectively; SFU for CHB patients were 27.2 ± 5.2, 29.1 ±
5.4, and 37.5 ± 6.0 respectively, t = 30.53, 31.17, and 21.75
respectively (p < 0.01 for all). In the AHB group, specific
CTLs had a different response to different epitope pep-
tides: Pol575-583<Env348-357<Core18-27, and t = 10.36
for Pol575-583 and Env348-357; 11.10 for Pol575-583 and
Core18-27; -4.35 for Env348-357 and Core18-27 (p < 0.01
for each comparison). Stimulation with non-specific HLA-
A0201-limited HCV Core132-140 peptide also led to an
increase in SFU with no significant difference between the
control group and negative group, t = -0.299, p = 0.77.
Examples of this ELISPOT analysis can be found in
Figures 4 and 5.
Relationship between HBV DNA level and the frequency
and function of HBV specific CTLs
No statistical differences were observed for the frequen-
cies of specific CTLs in HBV DNA positive and negative
AHB patients. However, a follow-up of AHB patients
revealed a clearance of serum HBV DNA and normali-
zation of liver function. Furthermore, the HBV-specific
Figure 2 The relationship between the frequency of peripheral
blood HBcAg18-27-specific CTLs and HBV clearance in AHB
patients. HBV infection in AHB patients was measured by the viral
load (HBV DNA amount) and level of HBeAg at weeks after
admission to hospital.
Figure 3 Relationship between the frequency of peripheral
blood HBcAg18-27-specific CTLs and liver injury in AHB
patients. Liver function tests (ALT and AST) were measured in
hospitalized AHB patients.
Figure 4 ELISPOT results from CHB patients. Sequence of
Pol575-58 is FLLSLGIHL, sequence of Env348-357 is GLSPTVWLSV,
sequence of Core18-27 is FLPSDFFPSV, sequence of HCV Core132-
140 is DLMGYIPLV; all are HLA-A0201 limited. Medium without
stimulation or cells was used for negative control, PHA for positive
control. 2 × 10E5 cells per well was used for the negative and
peptide stimulated groups, 1 × 10E4 cells per well was used for the
positive control. The final concentration of peptide was 10 μg/ml,
PHA 4 μg/ml. HLA-A0201 positive patients were chosen as the
research subjects.
Figure 5 ELISPOT results from AHB patients. Sequence of
Pol575-58 is FLLSLGIHL, sequence of Env348-357 is GLSPTVWLSV,
sequence of Core18-27 is FLPSDFFPSV, sequence of HCV Core132-
140 is DLMGYIPLV; all are HLA-A0201 limited. Medium without
stimulation or cells was used for negative control, PHA for positive
control. 2 × 10E5 cells per well was used for the negative and
peptide stimulated groups, 1 × 10E4 cells per well was used for the
positive control. The final concentration of peptide was 10 μg/ml,
PHA 4 μg/ml. HLA-A0201 positive patients during the first week of
hospitalization were chosen as the research subjects.
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CTLs response decreased gradually and was significantly
lower than that in the acute phase. This indicated that
the potent multiple-epitope CTL responses may be the
critical mechanism responsible for the viral clearance
(Figure 6).
Dynamic changes in peripheral blood lymphocyte subsets
in AHB patients
Numbers of CD3+CD8+ cells in AHB patients were
significantly higher than those in the healthy control
group from the first to the fourth week (for the first week
t = 2.766, p = 0.008; second week t = 3.451, p = 0.01).
Peak levels of CD3+CD8+ cells and the frequency of
HBcAg18-27-specific CTLs in AHB patients occurred in
the second week after admission. The number of CD3
+CD8+ cells was positively correlated with the mean fre-
quency of CTLs at each observation point (r = 0.492, p =
0.01), showing a certain relationship of growth and decline
between them (Figure 7).
We also found that although serum HBV DNA and
ALT stayed at a high level and NK and NKT cells were
relatively low for AHB patients at the first and the sec-
ond week after admission, NK and NKT cells gradually
increased to the normal range with the clearance of the
virus and the normalization of liver function. The num-
ber of NK cells was negatively correlated with the fre-
quency of HBcAg-specific CTLs during the six weeks of
hospitalization (r = -0.266, p = 0.05). NKT cell numbers
were lower in AHB patients relative to healthy controls
(p = 0.032) in the first week of admission (Figure 8).
NKT cells remained low in the following weeks but the
difference was not statistically significant.
Discussion
HBV is a double-stranded DNA virus that can cause
acute or chronic liver infection in humans. The antigen
cellular immune response plays an important role in the
pathogenesis of HBV infection and the clearance of
HBV, as has been emphasized in the literature [7].
HBV-specific CD8+ CTLs can kill the hepatitis B virus
via cytolytic and non-cytolytic pathways, but they are
also the main effector cells for liver injury. In acute
HBV infection, HLA class I-restricted CTLs respond
specifically to antigen epitopes of the viral membrane,
capsid and polymerase proteins; thus, multi-epitope-
and multi-clone-specific CD8+ CTLs can be detected.
On the other hand, the number of specific CD8+ CTLs
in the periphery in patients with chronic hepatitis B is
very small. Nakamoto et al. [8] found that in AHB
Figure 6 Dynamic changes of HBV antigen specific CTL
responses in AHB patients. CTL responses against three HBV
epitopes (Pol575-583, Env348-357 and Core18-27) were measured
by ELISPOT at different time points after admission to hospital.
Figure 7 The relationship between peripheral blood
lymphocyte subsets and HBV-specific CTLs. Dots indicate the
mean value. CD3+CD8+ cells and HBcAg18-27-specific CTLs of AHB
patients reached peak levels at the second week after admission.
There was a positive correlation between them (r = 0.492, p = 0.01).
The number of NK cells was negatively correlated with the frequency
of the HBV specific CTLs in AHB patients (r = -0.266, p = 0.05).
Figure 8 Levels of NKT cells in either healthy control group
(Normal) or AHB patients at different weeks (1 W - 6 W) after
being admitted to hospital.
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patients with normal immune function, a substantial
number of HBV particles are cleared before the liver
cells are injured, but a certain amount of the virus still
replicates in liver cells, leading to the induction of cyto-
lytic mechanisms and liver cell injury. Thus, HBV is
eventually completely cleared, although short-term liver
injury can be seen, which is clinically manifested as self-
limited AHB. Guidotti et al. [9] studied two chimpanzee
models with HBV infection and found that HBV DNA
in the serum and liver disappears before the peak in
serum transaminases. In the current study, we found
that HBcAg-specific CTLs can be detected in the per-
ipheral blood of AHB patients even in the early stages,
and their frequency changes dynamically. During hospi-
talization, HBV CTLs frequencies in AHB patients were
significantly higher than those in CHB patients and
healthy controls. When serum ALT levels were high,
HBV DNA levels decreased significantly. Among AHB
patients, 26.4% had negative serum HBV DNA before
admission; 50.9% had negative serum HBeAg; and 17.0%
had negative serum HBsAg. These findings suggest that
serum HBV levels were suppressed or partially cleared
before liver transaminase levels became elevated. Mean-
while, peak levels of peripheral blood epitope-specific
CTLs in AHB patients occurred in the second week
after admission, when the ALT levels had significantly
decreased. Peak levels of HBV epitope-specific CTLs
appeared later than serum ALT peak levels and lagged
behind serum HBsAg and HBV DNA peak levels;
furthermore, the higher the frequency of peripheral
blood HBV-specific CTLs, the earlier of the antigenic
diversion of HBeAg, suggesting that the high frequency
of specific CTLs in AHB patients may have played an
important role in clearance of the virus. However, the
frequency of specific CTLs in AHB patients was not
synchronous with liver cell injury or serum HBV clear-
ance, in other words, clearance of the virus occurred
earlier than liver cell injury, suggesting that not only
cytotoxic effects but also non-cytotoxic effects might be
involved in the virus clearance of AHB patients.
Our study indicates that not only was the frequency of
specific CTLs significantly higher in AHB patients than
in CHB patients, but also the response ability of HBV
antigen epitope-specific CD8+ was higher in AHB
patients (p < 0.05). The ability of different antigens to sti-
mulate specific CTL to produce INF-g was different; the
pattern observed was as follows: Core18-27> Env348-
357> Pol575-583, which may be related to the different
immunogenicity of the different regions of HBV antigens
[10]. The level of HBV Core18-27-specific response was
significantly higher in the acute phase in AHB patients
compared with those in convalescence (p < 0.05), which
proved that this antigen epitope might be the main target
site for host immune clearance of virus [11].
In addition to the characteristics of the specific
cell-mediated immune response observed in this study,
the non-specific cellular immune response had its own
features. The total numbers of peripheral blood cytotoxic
T lymphocytes (CD3+CD8+) in AHB patients in the early
stage of infection were higher than in the healthy control
group and among CHB patients. The peak of CD3+CD8+
cell numbers, meanwhile, appeared at the second week
after admission, and the dynamic changes of this cell num-
ber were basically the same as that of HBcAg-specific
CTL. A correlation was observed between the growth and
decline of CD3+CD8+ cell numbers and HBcAg-specific
CTL (r = 0.492, p = 0.01). These results suggest that the
number of peripheral blood CD8 + lymphocytes might
reflect CTLs frequency indirectly in AHB patients and was
helpful to predict the prognosis of an HBV infection.
NK cells are the first line of host defense against the for-
eign invasion of pathogenic microorganisms [12]. They are
usually activated in the early stage of a viral infection and
are particularly abundant in the liver [13,14]. Activated
NK cells play an important role in the recirculation of
virus-specific T cells and the induction of anti-viral immu-
nity in the liver [15]. Previously, we compared lympho-
cytes in the liver and peripheral blood of patients with
different types of hepatitis and found that NK cells in the
liver were significantly more abundant than in the periph-
eral blood [16]. This tendency shows that NK cells play an
important role in local immunity in the liver. Our study
analyzed peripheral blood NK cells in AHB patients and
found that dynamic changes in peripheral blood NK cells
were different from the trend of the frequency of HBcAg-
specific CTLs. The NK cells in these patients gradually
increased to the normal range as the virus was cleared in
the peripheral blood and liver function recovered and the
dynamic changes of peripheral blood NK cells negatively
correlated with the frequency of HBV-specific CTL (r = -
0.266, p = 0.05). These results suggest that NK cells play
an extremely important role in the effective clearance of
HBV in the early stage of infection.
NKT cells are highly heterogeneous effector cells with
immune and regulatory functions [17]. They possess the
characteristics of both NK cells (CD56+) and T lympho-
cytes (CD3+) [18]. NKT cells are very rich in the mouse
liver and account for 50% of intrahepatic lymphocytes,
mainly located at the hepatic sinusoids [19]. They play
an important role in the prevention of tumor metastasis
and the removal of viruses [20]. It was shown, by a
mouse hepatitis model induced by Con A or LPS plus
IL-12, that NKT cells could induce liver damage, and
the activated NKT cells disappeared from liver [21,22].
The activation of NKT cells is often accompanied by the
activation of NK cells, which then release cytokines that
prevent viral replication [23]. Therefore, it is thought
that NK cells might be effector cells for NKT cells [24].
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In the healthy control group, 2% of the CD3+ cells in
the peripheral blood expressed CD56, whereas in the
liver, this value was 30% [25,26]. In our study, the num-
ber of NKT cells in the peripheral blood of AHB
patients in the early stage of infection was significantly
lower than in the control group, and the dynamic
changes in NKT cells were basically the same as those
in NK cells. Based on these findings, we suggest that
NK and NKT cells accumulate in the liver and play an
important role in local immunity, resulting in a lower
frequency of NKT cells in the peripheral blood.
Conclusions
In summary, activated NK and NKT cells are involved
in the non-specific removal of virus at an early stage of
infection, particularly for viral clearance in liver cells
[27,28]. Specific cellular immunity induced by HBV
infection plays a key role in the total clearance of HBV.
During dynamic monitoring of the function and number
of specific CTL, NK, and NKT cells during acute HBV
infection, we found that changes had great clinical sig-
nificance in determining the prognosis of HBV infection
and in evaluating the chronic process.
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